Marker Therapeutics Inc (MRKR)

[poods]

I'm not convinced that MRKR management has its act totally together yet, however, there's no getting around the hard fact that Multi-TAA produces CRs in heavily pretreated lymphoma patients and it induces antigen.epitope spreading in both hematological and solid tumors. That was all achieved with negligible toxicity. Have any idea how rare that is in I-O or oncology in general?
The platform works and is non toxic. Period. Perfect for combination treatments. This company will either gain traction with cash infusion partnerships or get bought IMO.